KAVI Institute of Clinical Research focuses on four themes coupled with attractive career paths that are attracting the best talent in Africa and serve the best interests of the general
The Clinical Trials track runs HIV vaccine trials in addition to trials for other products including chemotherapy drug trials. Finally, the Knowledge Translation track brings research, policy
IKAVI Institute of Clinical Research focuses on four themes coupled with attractive career paths that are attracting the best talent in Africa and serve the best interests of the general
KAVI Institute of Clinical Research focuses on four themes coupled with attractive career paths that are attracting the best talent in Africa and serve the best interests of the general.
KAVI - ICR and Cherami Initial Discussions on Cherami Cancer Institute Establishment
This meeting between KAVI-ICR and Cherami, presided over by Prof. Omu Anzala and Mr. Wei Xiolin, was to formally introduce Dr. Wei Liao, CEO and Founder of EzLife Bio Inc.
Also present in the meeting were KAVI-ICR members Dr. Marianne Mureithi, Dr. Kefa Bosire, Dr. Moses Masika, Mr. George Kaiyare and Mr. George Ichoho, Cherami members Tony Gichuru and Mark Xu.
Dr. Liao, a well-known and respected scientist in both academia and industry, provided the collective group a presentation on EzLife Bio’s technology EFIRM and its potential applications in clinical and laboratory settings using a tissue, plasma and saliva samples.
It was agreed that this technology would prove to be useful for the African continent and would initially be housed in the KAVI-ICR laboratory for validation and to explore its applications for non-communicable and infectious diseases currently affecting the region.
Additionally, KAVI-ICR will provide a list of infectious diseases that EzLife Bio could create assays for and write up a proposal for the testing of circulating tumour DNA (ctDNA) in Lung Cancer.
University of Nairobi and Cherami Cancer Institute
Members of KAVI-ICR; Prof. Anzala, Dr Mureithi, Dr. Bosire and Mr. George Ichoho, this morning witnessed the signing of the University of Nairobi and Cherami Investment Group. The partnership which will kick-start the process towards the establishment of the University of Nairobi Teaching and Research Hospital with a state of the art Cancer Research Institute is the first Phase of the development. The MOU was signed by the University of Nairobi Vice Chancellor Prof. Peter Mbithi and the President of Cherami Investment Group. Also present was Cabinet Secretary, Ministry Education, Amb. Dr. Amina Mohamed and the Incoming University of Nairobi Council Chairperson, Dr. Julia Ojiambo
Defining HIV interaction at the Mucosa
KAVI-ICR in collaboration with USAID, North Western University USA, Human Immunology Laboratory – Imperial College London, International AIDS Vaccine Initiative (IAVI) representatives has successfully established studies on HIV interaction at the mucosa. These studies will contribute to the development of a universal effective HIV Vaccine and ultimately tackle the questions related to the early stages of HIV acquisition/transmission and develop future prevention strategies.
International Conference on Health (ICH 2018)
Processional march to mark HIV Vaccine Awareness Day in Kangemi on 18th May 2018
Every year on 18th May, the world marks the HIV Vaccine Awareness Day (HVAD). It is a day set aside to raise awareness of the continuing efforts by scientists to develop a vaccine against HIV- the virus that causes AIDS. It is also a day to honour all those who, in one way or the other, have contributed towards this global effort. This year, KAVI-Institute of clinical research (KAVI-ICR) of the University of Nairobi commemorated the day in Nairobi at the Kangemi Health centre.
The team from NCBS led by Lt. General Velu Nair, met the Vice-Chancellor, Prof. Peter Mbithi when they paid a courtesy call on him on March 21, 2018.
The University of Nairobi’s KAVI-Institute of Clinical Research (KAVI-ICR) and the National Centre for Biological Sciences (NCBS), India, have established and initiated a collaboration to spearhead vaccine development through enhanced technology. According to the Director, KAVI-ICR, Prof. Omu Anzala, the partnership will see the team expand metagenomics sequencing from selected target groups in India and Africa and inform the newly emerging pathogens such as Chikungunya and Dengue in their virology, pathology, the point of care diagnostics and vaccine designs.
Initiation of the Collaboration between NCBS (India) and KAVI-ICR (University Of Nairobi, Kenya) while training University of Nairobi staff on flow cytometry 19th to 23rd March 2018.
Friday 05th October 2018 from 7.00am to 8.30am
Venue: KAVI - ICR Boardroom